Lam Research reported Q4 2026 results on July 29 and is now trading at $252.35, extending a decline that has erased roughly 42% from the late-June peak near $433, with the gap between what analysts say the stock is worth and where the market has priced it continuing to widen.
The price destruction has accelerated. After closing at $269.61 following the initial post-earnings reaction, LRCX fell another 6.4% on July 30 to $252.35 — now down 21% on the week and 33% over the past month. The selloff is not a company-specific verdict; it is a sector-wide repricing. Peers moved in lockstep on the day: AMAT fell 7.8%, MKSI dropped 9.6%, UCTT shed 10.9%, and ICHR lost 13%. and each gave back 6-7%. The semiconductor equipment complex continues to reprice as a unit, and LRCX is moving with it.
The analyst-market divide is now the defining feature of this stock. The Street's consensus price target is $375 — nearly 49% above where LRCX trades today. Every analyst action over the past three weeks has been an upward revision, not a cut. Evercore ISI raised its target to $355, Morgan Stanley moved to $404, Stifel lifted to $425, and BofA went to $480 — all well above the current print. Bulls point to projected WFE growth above 30% in 2027 as cleanroom constraints ease, Lam's leading share in etch technology, and a customer base anchored by TSMC, Samsung, and Micron. Bears counter that high customer concentration, competitive pressure in etch and deposition, and a valuation that still carries premium multiples — the PE has compressed sharply but remains near 29x — leave limited margin for error if the spending cycle disappoints. The EV/EBITDA has contracted nearly 10 turns over the past month, reflecting just how much the market has moved against the Street's thesis.
Short sellers are still absent from this story. Short interest nudged up 8.7% over the past week to 2.3% of the free float, but that remains a low absolute level with no conviction behind it. Borrow costs have fallen 43% over the same period to 0.28%, and availability is effectively unlimited — over one billion shares available. The CEO sold $11.7 million in stock at $390 on July 2, and the independent chairman sold $6.1 million at $335 on July 13 — both well above current prices, a reminder that insiders were exiting into what now looks like a much higher level. The selling pressure on the stock has come from long holders, not short-side accumulation.
Today's further move to $252 tests whether the earnings print itself has changed the fundamental argument — or whether this remains a macro and sector de-rating that the results cannot stop regardless of their quality.
See the live data behind this article on ORTEX.
Open LRCX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
